Cours Novavax, Inc. Nasdaq
Actions
US6700021040
Recherche biotechnologique et médicale
CA 2024 * | 846 M 772 M | CA 2025 * | 986 M 901 M | Capitalisation | 572 M 523 M |
---|---|---|---|---|---|
Résultat net 2024 * | -112 M -102 M | Résultat net 2025 * | -90 M -82,2 M | VE / CA 2024 * | 0,07 x |
Trésorerie nette 2024 * | 510 M 466 M | Trésorerie nette 2025 * | 482 M 440 M | VE / CA 2025 * | 0,09 x |
PER 2024 * |
-5,66
x | PER 2025 * |
-103
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 94,33% |
Dernier transcript sur Novavax, Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 57 | 23/01/23 |
John Trizzino
PSD | President | 64 | 10/03/14 |
James Kelly
DFI | Director of Finance/CFO | 58 | 16/08/21 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Richard Rodgers
BRD | Director/Board Member | 57 | 29/10/22 |
Gregg Alton
BRD | Director/Board Member | 58 | 01/11/20 |
David Mott
BRD | Director/Board Member | 58 | 16/06/20 |
Varia. 1 janv. | Capi. | |
---|---|---|
+1,51% | 42,75 Md | |
+49,22% | 41,61 Md | |
+8,57% | 41,34 Md | |
-12,36% | 26,59 Md | |
+8,92% | 25,49 Md | |
-25,13% | 18,12 Md | |
+29,17% | 12,24 Md | |
-3,12% | 11,76 Md | |
+6,35% | 11 Md |